OmniComm Systems, Inc.'s TrialMaster(TM) EDC Solution Selected by Leading Medical Device Manufacturer for Phase IV Cardiovascular Device Study

FORT LAUDERDALE, FL--(Marketwire - November 17, 2009) -

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that a leader in the medical device industry has selected OmniComm’s TrialMaster EDC solution for the data capture of a Phase IV cardiovascular study. The 24-month, 7-site study will enroll 100 subjects.

“We look forward to continuing our successful collaboration with this device company,” remarked Stephen Johnson, COO of OmniComm Systems. “Our flagship EDC solution, TrialMaster, has already proven to be an efficient and reliable data capture system for 12 of this customer’s studies during the past 5 years. This is proof positive that the high quality of our EDC solutions and our outstanding customer service continue to generate the high percentage of return business needed to sustain our current rate of growth.”

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small, to large-scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company’s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.